Individuals with clinical WHO stage III/IV had nearly 3.1 times increased risk of developing TB as compared to patients in clinical WHO stage I/II after controlling for past opportunistic illness, IPT use and CD4+ cell count (AHR = 3.05; 95% CI: 1.61- 5.81). The gene discussed is CD4; the disease is tuberculosis.